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Malignant melanoma of gastrointestinal (GI) tract is a less common condition especially in 
eastern countries and can be either primary or metastasis. Most of the cases are secondary 
melanoma. GI metastases are frequently found during autopsy, only small proportion of the 
patients can be detected while living (2#5% of the patients). Clinically, a primary GI 
malignant melanoma is suggested if the patient has no obvious primary cutaneous lesion or 
other extra#intestinal disease especially the ocular system. Malignant melanoma of 
anorectum is the most common site of the primary tumor of GI tract. For metastasis, small 
bowel is the most frequently site followed by stomach, large bowel and esophagus. Mucosal 
melanoma pursued more aggressive nature and poorer prognosis than other subsets of 
melanomas. Prognosis of malignant melanoma of GI tract is very poor because of difficult to 
diagnosis. 
Malignant melanoma of GI tract can present as abdominal pain, upper or lower GI tract 
bleeding, obstructive jaundice, obstruction or perforation. Several case reports demonstrated 
small bowel obstruction from intussusceptions of malignant melanoma. The diagnosis can 
be made by GI endoscopy or imaging radiographic studies. The definite diagnosis is the 
pathological examination. Management of GI malignant melanoma depends on the location 
and number of the lesion. Surgical resection for primary melanoma of GI tract is the 
mainstay treatment and provides a chance for cure. For metastatic disease, multidisciplinary 
approach is the best option. Surgery is the alternative way to use in selected patient.   
			
Melanoma originates from melanocyte, a pigmented, dendritic#like cell located in epidermis 
of skin, eye, epithelium of the nasal cavity, oropharynx, anus and genitourinary system. The 
diagnosis of melanoma includes assessment of the architectural and cytological features 
combine with the clinical examination. The only staging system of malignant melanoma is 
used for cutaneous melanoma because of the high incidence rate compare to non#cutaneous 
group, accounts about 90% of all melanoma. Of the remaining forms of melanoma, ocular 
melanoma accounts for 5%, mucosal melanoma for 1% and melanoma of unknown origin 
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for 2%. Within the mucosal subgroup, half of them are head and neck origin followed by 
anorectal, female genital, and urinary tract tumors respectively. The pathological staging of 
primary tumor uses the tumor thickness and ulceration. Ulceration is defined as the absence 
of the intact epithelium overlying a major portion of the tumor. Ulceration is the result of 
the thickness of tumor and has a strong correlation to survival.  
 Recently, American Joint Committee on Cancer (AJCC) presented the 7th edition of the 
melanoma staging system in 2009. Differences from the 6th edition (2002) included the used 
of mitotic rate to classify stage 1a and 1b, used of immunochemical detection of nodal 
metastasis and no lower threshold to define positive nodal status. For stage IV disease, the 
staging system is not change. The site(s) of metastases and elevated serum levels of lactate 
dehydrogenase (LDH) are used to divided M stage to three categories; M1a, M1b and M1c. 
The definition and survival were shown in table 1. 
 
M stage Site Serum LDH 
One#year survival rates 
% 
M0 No distant metastases NA NA 
M1a 
Distant skin, subcutaneous, or 
nodal metastases 
Normal 62 
<0.0001 M1b Lung metastases Normal 53 
M1c 
All other visceral metastases 
Any distant metastases 
Normal 
Elevated 
33 
Table 1. Modification of the 7th AJCC classification of metastatic melanoma.  
Most of melanoma in GI tract is metastases. Only 2#15% of all GI melanomas are 
primary. Whenever a seemingly primary melanoma is detected in GI tract, it is prudent 
to conduct a through clinical investigation to consider the possibility of metastatic 
disease including history, physical examination and investigations. Carefully history 
taking and comprehensive physical examination are the initial crucial step of the 
approach. Skin and eye examination should be mandatory examination in all patients. 
Gynecological and abdominal examination include rectal examination should be 
performed for the next step.  
Ozdemir et al. proposed criteria for diagnosis primary bronchial melanoma to be defined as 
a primary lesion that can apply to GI melanoma as well. The criteria including (1) there is 
only single lesion in the surgical specimen (2) there must be no previously excised skin 
tumor (3) no previous ocular tumor (4) morphology must be compatible with primary 
tumor (5) there must be no other demonstrable melanomas at the time of surgery (6) 
findings should be confirmed by careful autopsy. The lesions that not fulfill these criteria 
should be termed secondary. The problem of the criteria is we could know the exact 
diagnosis after the autopsy when patient passed away. Then, these criteria did not have an 
impact to the treatment, only for the epidemiology. Blecker et al. suggested the following 
criteria for a diagnosis of primary intestinal melanoma: 1) no evidence of concurrent 
melanoma or atypical melanocytic lesion of the skin, 2) absence of extraintestinal metastatic 
spread of melanoma, and 3) presence of intramucosal lesions in the overlying or adjacent 
intestinal epithelium. 
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Small bowel is the most common site of GI melanoma and bleeding is one of the most 
frequent presentations of the patients. Therefore, a GI endoscopy with magnification should 
be the procedure of choice to diagnose malignant melanoma of GI tract. Multiple black, 
depressed lesions (1+ 5 mm in diameter) with a “bull’s eye” appearance are usually viewed 
in the GI mucosa (Figure 1). At present endoscopic ultrasonography (EUS) guided fine 
needle aspiration (FNA) may play an important role for cytological diagnosis in the patients 
with advanced disease (Figure 2).  
 
 
Fig. 1. Endoscopic view showed multiple typical black color lesions in the second part of 
duodenum. 
 
 
Fig. 2. EUS#guided (A) FNA for cytological confirmation (B) in the patient with advanced 
malignant melanoma. 
www.intechopen.com

	
				
	
		

 
			

Small bowel metastatic may present as varying sized single or multiple nodules that can 
have polypoid or infiltrating appearance. Central ulceration can occur when lesions 
outgrow their blood supply, giving a “target” appearance on barium study. The target sign 
can be found with other hematogenous metastases such as lymphoma or sarcoma. For small 
bowel metastatic, the lesion can be intraluminal involvement and act as leading point for 
intussusceptions.  
Capsule endoscopy (CE) is the current standard and one of the most sensitive investigations 
for detection of small bowel lesion. The finding could be a polypoid lesion with central 
umbilication or an ulcerative lesion with bleeding.  Prakosa et al. reported a series of 21 
patients diagnosed malignant melanoma and underwent positron emission tomography 
(PET) scanning and CE. They suggested that CE could identify and provide confirmation of 
small#bowel involvement in patients with metastatic melanoma after PET scanning. These 
two investigations are recommended as part of the work#up of all patients with or without 
GI symptoms.  
 	!" #		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	"$#
Computed tomography (CT) is the most commonly used imaging technique for staging and 
follow up in the malignant melanoma patients. Two studies have compared staging with 
Positron emission tomography (PET) and CT scan in all stages. Both studies found PET to be 
superior in terms of sensitivity and specificity to CT in all stages of Melanoma. In the 
contrary, Krug et al. demonstrated inferiority of PET to CT for the detection of lung and 
liver metastases.  
Magnetic resonance imaging (MRI) is a good investigation for detection of brain and bone 
metastases. For anorectal region, MRI and endorectal ultrasonography are the good 
investigational methods for preoperative evaluation both of primary tumor and local nodal 
status. In one prospective study of 64 patients, whole#body MRI has been reported to have 
an overall accuracy for the detection of lesion slightly lower than PET#CT (78.8% vs. 86.7%), 
but the sensitivity for the detection of bone and liver metastases was better than PET#CT.     
%&	!"&#
Positron emission tomography (PET) is an advanced diagnostic imaging technique. This 
technique exploits the increased metabolism of glucose in malignant viable cells. 18F#
fluorodeoxyglucose (FDG) is one of the most commonly used radioisotopes. FDG is 
transported into tumor cells like glucose molecule. There is a many#fold increase in glucose 
metabolism in malignant tumors as compared with normal cells, therefore, the different in 
metabolism of tumor call and normal tissue can be detected by this technique. The potential 
benefits of FDG#PET for melanoma included the detection of locoregional and distant 
metastasis for staging.  
The presence or absence of regional lymph node metastases is an important prognostic 
factor for patients with melanoma. FDG#PET has shown a limitation of sensitivity and wide 
variation of the data from previous studies. The sensitivity of FDG#PET is varied from 8% to 
100%. Moreover, in the subgroup of subclinical nodal disease in stage I and II melanoma, 
the sensitivity of FDG#PET is only 14#17% whereas, sentinel node biopsy reached 86#94%. 
Crippa 
 . identified the correlation between size of lymph node and sensitivity; 
sensitivity is 23%, 83% and 100% for lymph node less than 5mm, 6#10mm and greater than 
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10 mm in diameter, respectively. Therefore, FDG#PET might not be the investigation of 
choice for locoregional evaluation especially for clinically nonpalpable group.   
For the distant metastatic evaluation especially in curative intent resected patients, the 
precise identification of the location and number of metastatic lesions could be important for 
surgical planning. From several studies, FDG#PET has been shown to be more accurate than 
conventional modalities such as ultrasonography, CT, and MRI. Then, FDG#PET is most 
commonly used for suspected or known distant metastases. The sensitivity is varied from 
79% to 92% and specificity is varied from 86% to 90%. Several reports identified the 
influence of therapy by FDG#PET, 17# 48% of patients were changed their treatment plan. In 
the same way, FDG#PET is highly sensitive and specific for detection or restaging of 
melanoma. Prichard 
! reported the sensitivity and specificity of FDG#PET for detection 
of recurrent melanoma, 74#100% and 67#100%, respectively. Figure 2 is the one example of 
PET scan of intraabdominal metastatic of melanoma.  
  
 
Fig. 3. PET scan revealed multiple metastasis lesions of malignant melanoma of 
gastrointestinal tract such as pancreas, liver and small bowel. 
%		
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GI tract is not the normal organ that contain of melanocytes. Then, how be possible primary 
melanoma can develop in GI tract? One explanation is neural crest cells that demonstrated 
in the intestines, these cells have a potential to develop to mature melanocyte. Another 
reason, the aberrant migration of melanocytes that usually migrate from neural crest to the 
epidermis, hair follicles, oral cavity, nasopharynx, uvea, leptomeninges, and inner ear 
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during early embryogenesis. These are the reasons that why melanoma can be found in the 
gastrointestinal tract.  
Primary GI melanoma can arise in various GI mucosal sites, including oral cavity, 
esophagus, stomach, small bowel, colon and anorectum. Distinguish between primary and 
metastatic from an unknown or regressed cutaneous melanoma may be difficult. Clinically, 
a primary GI melanoma is suggested if the patient has no obvious primary cutaneous 
melanoma from history and physical examination. Moreover, the patient has an isolated GI 
lesion without extraintestinal metastases. For histologically, the presence of atypical 
melanocytic cells in the basal layer of the epithelium and extending in a pagetoid fashion in 
to more superficial epithelium, may be reported in 40#100% of primary GI melanoma. The 
surgical treatment and the outcomes were depended on the organ of tumor involvement. 
Then, we divided primary melanoma in this section to organ specific. Summarized of the 
survivals was showed in the table 2. 
 
 	

 

Oral cavity 27#38.9 30#40% 
Esophagus 12#13.4 4.2#14 % 
Stomach 5#12 0 
Small intestine 16 10% 
Colon  27.5 21#56% 
Anorectum 15#28.6 17#30.6% 
Gallbladder and biliary tract 20.1#41 29 % 
Table 2. Summarized of survivals divided by primary organ involvement.  
'		
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Primary malignant melanoma of esophagus is the rare condition, accounts only 0.1#0.2% of 
primary esophageal tumors. Whereas, cadaveric study from De la Pava 
. demonstrated 
the presence of melanocytes in 4% of all esophageal specimen examined. Then, there are 
other entities of melanotic condition that can be found in esophagus. One benign condition 
called esophageal melanocytosis need to differentiate from the esophageal melanoma. This 
condition described the distribution of melanocytes in the basal layer of the esophageal 
squamous epithelium. The incidence is about 0.07#2.1% from previous reports. For primary 
esophageal melanoma is commonest in older males and more found in the middle and 
lower esophagus.  
Patients may present with symptoms of dysphagia, retrosternal discomfort, weight loss, 
regurgitation or melena. After careful history and physical examination, barium swallow 
and/or endoscopy is the next investigation same as all esophageal lesions. The characteristic 
endoscopic appearance of primary malignant melanoma is a polypoid, irregularly 
pigmented, obstructive esophageal tumor. The tumor most often is polypoid; the 
nonpolypoid form is extremely rare. The color of the tumor may vary from black to white. 
An ulcerative lesion of the mucosa can be found in some case, then some tumors may be 
difficult to differentiate from esophageal carcinoma. Most of the cases are grossly 
pigmentation, but not almost always. The endoscopic biopsy can diagnose only half of the 
patients due to submucosal nature of the tumor. Up to 25% of all esophageal melanomas are 
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amelanotic. Presence of associated benign melanocytes or in situ melanoma from 
pathological examination favors the diagnosis of primary, rather than metastatic. If primary 
malignant melanoma is suspected at endoscopy, immunohistochemical staining of biopsy 
specimens is essential for diagnosis. 
Regard to difficulty of the diagnosis, half of the patients are stage IV when diagnosed. The 
median survival is about one year and 5#year survival varied from 4.2% to 14%. The 
mainstay of the treatment is still surgical resection with dissection of the regional lymph 
nodes. Compared with other esophageal tumors, wider margins of resection are required. 
For early#localized lesion, radical resection had a significantly longer survival compare to 
local excision. Radiation can increased the mean survival rate from 14.2 months to 16.7 
months, while adjuvant chemotherapy have a limited benefit. Only some case reports that 
demonstrated the long#term survival from surgical resection combine with chemotherapy. 
There are some alternative techniques such as endoscopic mucosal resection and localized 
ablative approaches were proposed in case report but the data still limited.   
'	!
Primary melanoma of stomach is the very rare disease entity and related to poor outcomes. 
Most of the reports are the case report then, the data is quite limited. The presenting 
symptoms of gastric melanoma are non#specific including nausea, vomiting, abdominal 
pain, weight loss and anemia. Perforation and/or upper GI bleeding can be presented as an 
initial diagnosis in some patients. Barium study, endoscopy and CT scan are the most 
common investigational methods. In the same way of esophageal melanoma, pigmentation 
of the lesion is the most clues for diagnosis and found in the majority. The median survival 
is usually less than 1 year. Cheung 
 ! reported 18 cases of primary gastric melanomas 
with the median survival is only 5 months without 5#year survival. Regard to limitation of 
the data, it is difficult to conclude that which operations are the appropriate surgical 
procedures of primary gastric melanoma.  
'	

(
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Primary melanoma of gallbladder is extremely rare condition as well as isolated metastasis 
to gallbladder. Regard to clinical presentation, involvement of the gallbladder rarely 
produces symptoms. Some case reports presented acalculous cholecystitis as a clinical 
presentation of these patients. Therefore, it is difficultly to diagnose melanoma of 
gallbladder preoperatively. Abdominal ultrasonography is a useful, easy, and inexpensive 
modality for assessing a gallbladder lesion. CT scan and Magnetic resonance 
cholangiography may add more information. Surgical resection of gallbladder is the 
treatment of both primary and metastatic lesions. The mean survival times for primary 
gallbladder melanoma is 20.1 months and for metastatic is 8.4 months, with few patients 
surviving longer than 2 years. 
In 1963, Zaide first described primary malignant melanoma of common bile duct. This is 
also rarely disease entity same as the others primary GI melanoma. The existence of 
melanocytes in bile duct tissue is truly possible. Melanocytes derive from cells of the neural 
crest and can migrate throughout the body. They have been definitely identified in areas of 
endodermal origin, including gallbladder. The symptoms of this tumor mostly presented 
with obstructive jaundice. In most of the cases, the diagnosis can be made after the time of 
surgery. Wagner 
 . reported the review of 6 cases of primary malignant melanoma of 
common bile duct from 1963 to 2000.  
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Fig. 4. Gastroscopy revealed multiple lesions of metastasis malignant melanoma in the 
stomach (A&B).  
All of the patients underwent surgery including 4 Whipple operations, 2 partial 
hepatectomies and one resection of common bile duct. Three of them (2 Whipple and 1 
hepatectomy) dead within 6#18 months from distant metastasis whereas three of patients 
didn’t mention about follow up period. Therefore, it is not possible to conclude the optimal 
surgical option for this disease due to very limited of the data. There are also had a few 
literatures that reported the extremely rare primary malignant melanoma of intrahepatic 
duct and liver in a case report format. Because of the limitation of the data, then we not 
presented the detail of these disease entities in this chapter.   
'%	

()

Cutaneous melanoma is the most common types of the tumor metastasis to GI tract which 
small intestine is the most common site of metastatic melanoma in the GI tract. However 
primary melanoma of small intestine is not common. Small bowel lesion can present with 
bleeding, abdominal pain, obstruction, weight loss and malabsorption. Intussusception can 
be a presenting symptom of small bowel melanoma. Diagnosis of small intestine lesion is 
typically made by contrast imaging study (small bowel follow#through), CT scan, 
endoscopy (push, single or double balloon and capsule endoscopy) and PET. Primary 
intestinal melanoma tends to be more aggressive and worse prognosis than cutaneous 
origin. The possible reasons are due to late diagnosis and rapidly growth of the tumor in the 
rich vascular and lymphatic supply of the intestinal mucosa. 
Surgery is the treatment of choice in patients with primary or metastatic intestinal 
melanoma. Segmental resection with adequate free margins is a recommended procedure. 
Morbidity and mortality of this type of surgery is very low. Systemic adjuvant therapy has a 
limited role for this disease. The median survival rate is 16 months and 5#year survival rate 
is 10%. 
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Primary melanoma of the colon is also a rare clinical entity. Khalid 
. (2011) reported their 
review study of 12 patients with primary melanoma of colon. Right#sided colon is the most 
common location of the disease; about 65% of the patients. Lower GI bleeding is the most 
common presentation (50%) followed by abdominal pain (20%), obstruction (20%), and 
weight loss (16%). Amelanocytic colon melanoma is found in 14% of the cases.  
For localized disease, surgical resection is the mainstay of the treatment. We cannot 
conclude that what is the standard of the operation because of the limitation of the data. 
Most of the patients in the previous studies underwent the oncologic colon resection same 
as adenocarcinoma. The prognosis of primary malignant melanoma of the colon seems to be 
better than other types of primary mucosal melanomas. However, colon melanoma is still 
aggressive than cutaneous origin. One#year and five#year survival rates are 37#60% and 21#
33%, respectively and the median survival is 27.5 months.      
'*+	
In 1857, Moore first described anorectal melanoma, a rare and very aggressive tumor with 
the extremely poor prognosis. The incidence is less than 1% of all melanomas and about 2 # 
4% of all anal malignancies. Majority about two#third of all lesions are pigmented. Two#
third of anorectal melanoma is located within the anal canal or at the anal verge and the 
others demonstrated in the rectum. Presentation is often nonspecific symptoms and 
indistinguishable from other conditions in this area such as rectal bleeding, palpable of anal 
mass, anal pain or discomfort. Some of the patients underwent an excision due to 
misinterpreted as a thrombosed hemorrhoid or anal polyp. Anorectal melanoma is 
diagnosed histologically by melanin pigment. However, immunohistochemical staining of 
melanoma antigen such as HMB#45 and S#100 protein are adjunctive for diagnosis. 
Unlike cutaneous melanoma, noncutaneous origin are more likely to be found metastasized 
to locoregional lymph node or distal organ when the time of diagnosis. For anorectal 
melanoma, incidence rate for locoregional lymph node is 61% and distant metastases are 
29%. Surgery still is the mainstay of the treatment for primary anorectal melanoma. The 
extent of resection (wide local excision versus radical resection) and extent of 
lymphadenectomy remain debated. Early some studies proposed radical resection like 
abdominoperineal resection was associated with the better outcomes. Unfortunately, other 
studies have reported similar patterns of recurrence and survival in patients undergoing 
local excision. Unlike anorectal adenocarcinoma, in the study from Memorial Sloan#
Kettering, demonstrated lymph node metastases did not predict outcome of patients 
undergoing radical resection. Moreover, prophylactic bilateral inguinal lymphadenectomy 
in the patients with clinically non#palpable lymph node has not shown to improve survival. 
The details of results from previous studies were summarized in the table 3.  
Change of practice patterns over the time depend on the new data that suggested local 
recurrence and survival are not associated with extent of resection. Moreover, recurrences of 
primary anorectal melanoma after surgery are more commonly distant and lethal. Then, 
local excision is the appropriate surgical management for localized primary anorectal 
melanoma. More radical resection and nodal resection may be needed in selected patients 
with clinically bulky tumor, involved sphincter complex or nodal positive including 
locoregional and inguinal area. 
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(1990) 
1974#
1990 
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(1993) 
1973#
1987 
55 # # #  

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(1995)  
1929#
1993 
85 # 
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
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#  
#
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(2004)
1977#
2002 
40  # 

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
14 
%

! 
(2006) 
1984#
2003 
46 


# 


# 
&'

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. 
(2008) 
1997#
2006 
79 # #  # 
(
! 
(2009) 
1960#
1999 
251  # 


# 
Table 3. Summarized of previous studies of primary anorectal melanoma (DFS: Disease free 
survival, OS: Overall survival, NS: not significant).  
*		
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Survival rate of stage IV melanoma patient is really worse, typically measured in months 
rather than years. Recurrence is identified about one#third of the patients, most of them 
recur at the regional nodes. For distant metastasis, almost major organ and tissue can be a 
site of metastases. Commonly of metastatic image is a wide spreading disease then role of 
surgical management is often palliative. In a retrospective review of 4,426 patients with 
stage IV melanoma treated at the John Wayne Cancer Institute, only 35% of all cases 
underwent surgical resection. These patients had a 5#year overall survival of 23% compared 
with 6% in those who were not surgical candidates (p< 0.001). Surgery with the intent of 
providing long#term survival should be considered only when all sites of disease can be 
completely removed. Therefore, a careful evaluation is an importance step of management 
and for looking to exclude others organ involvement. Regard to palliative intent, patient’s 
status, comorbidities, symptoms and life expectancy are the clues to decide the operative 
procedure.  
Preoperative evaluations include history taking, physical examination and assessment 
investigation such as ultrasonography, CT scan and MRI are a useful tool to evaluate status 
of the patients. CT scan is the most commonly used staging modality and has sensitivity 
about 60%. PET scan seems to have more sensitivity than CT scan, previously the sensitivity 
was reported in range from 70#100%. There are some reports proposed that the precise 
preoperative imaging can change surgical decision making 17#48%.        
The GI tract is an uncommon site for malignant metastases, only 2#5% of these patients can 
be detected clinically. However, melanoma is one of the most common tumors that 
metastasis to GI tract. Small intestine is the most common size. GI metastases are usually 
associated with disseminated disease. From previously studies, the median survival time is 
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only 5#11 months in secondary GI melanoma and estimated 5#year survival is usually less 
than 10%. Depend on the nature of the disease, the intent of surgical treatment usually for 
palliation. Surgery can relive the symptoms about 70#90% of the group especially 
obstruction, bleeding and perforation. The morbidities and mortalities of GI surgery are 
acceptable usually mortality less than 5% from previous studies.  
One paper from Memorial Sloan#Kettering Cancer Center reported 68 patients, who 
underwent surgical exploration for metastatic GI melanoma from total 7965 melanoma 
patients. The most common presentations are anemia (60%), abdominal pain (59%) and 
bleeding (44%). Sixty#two from 68 of patients had small bowel involvement. The median 
survival was estimated to be 8.2 months (6.9#11.4 months). The 1#, 2# and 5#year survivals 
were 35%, 23% and 18%, respectively. The significant factors from multivariate analysis 
were included preoperative serum LDH (p< 0.01) and residual disease (p= 0.03). Ninety 
percent of the patients had palliation of symptom after surgery.  
Another large series of secondary abdominal melanoma from M.D. Anderson, 251 patients 
was enrolled from the year 1970#1991. The common metastatic organs are small bowel 
(62%), mesenteric lymph nodes (45%), liver (37%) and stomach and duodenum (31%). The 
median of interval time after diagnosis was 38.5 months (1#258 months) and 13% of the cases 
developed intraabdominal recurrence during the first year of follow#up period. The median 
survival is 8 months in only intestinal metastatic group, 5 months in only visceral metastatic 
group and 4 months in both metastatic organs group. For palliative surgical resection, the 
median survival was increase significantly from 5 months in non#surgical group to 11 
months in surgical group (p< 0.0001). This benefit of the palliative surgical resection is 
concordant to our study that previously reported. In the 86 patients’ subgroup that had 
severely symptoms, surgergical approach was associated with longer symptom#free periods 
compared with non#surgical approach significantly (p< 0.0001). The multivariate analysis 
revealed that complete tumor removal, only intestinal metastasis and interval time of 
recurrence after diagnosis greater than 48 months were significance associated to better 
overall survival (p= 0.0001, =0.002, =0.005, respectively). Concomitant to most of the reports 
that supported complete resection, GI tract as a first site of metastasis, longer of disease free 
interval or interval from diagnosis, and lower level of LDH were associated to better 
outcomes. Summarized of favorable factors from multivariate analysis was in table 4. 
 
$%
# Complete removal of the tumor 
# Intestinal metastasis without others abdominal visceral involvement 
# Interval time of recurrence after diagnosis greater than 48 months 
# GI tract as a first site of metastasis  
# Presence of extra#abdominal disease 
# Preoperative serum LDH level < 200 u/L 
Table 4. Summarized of favorable factors from multivariate analysis. 
From these data, we can summarized that for secondary GI melanoma, particularly if the GI 
tract is the first site of metastasis, the curative surgical resection should be strongly 
considered not only for palliation of symptoms but also for improvement in survival. 
Although, improvement of survivals is only in the number of months, but surgery can 
provide significant improvement in quality of life of the patients with acceptable operative 
morbidity and mortality.  
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Over the past 50 years, more than 100 randomized clinical trials have investigated cytotoxic 
chemotherapeutic agents and immunostimulants such as Bacille Calmette#Guerin (BCG), 
)
*
, and levamisole. Interestingly, nonspecific immunotherapy declined 
as more active immunostimulatory cytokines, in particular interferon (IFN), came to clinical 
practice. In this chapter, we briefly presented the alternative management of surgery 
including chemotherapy, immunotherapy, vaccination and radiation in the setting of 
adjuvant and metastatic treatment.  
, !!	
Most of the data are in the setting of treatment of metastatic disease. Apart form IL#2, 
Dacarbazine (DTIC) is one of the two agents that were approved from U.S. Food and Drug 
Administration (US#FDA) for the treatment of advanced melanoma. The response rate was 
19#28% from previous studies. Unfortunately, no any studies demonstrated the benefit of 
overall survival of DTIC compare to supportive care in the advanced melanoma patients. 
Temozolomide (TMZ), an analog of DTIC with similar activity, the potential benefit over 
DTIC is available in oral form. Several studies suggested TMZ is active against CNS 
metastases. Therefore, TMZ should be considered in the patient with brain metastases 
although, no difference of overall survival compare to DTIC.  
The combination of chemotherapeutic agents have been developed including BOLD 
(Bleomycin, Vincristine, Lomustine, and DTIC), CVD (Cisplatin, Vinblastine, and DTIC), 
The Dartmouth regimen (DTIC, Cisplatin, Carmustine, and Tamoxifen). The response rate 
was improved, but no difference in survivals compare to DTIC alone. Moreover, the toxicity 
was increased when used of the combine regimens.     
,!	
High dose of the Interferon α#2b (IFN α#2b) is the only adjuvant therapy for stages II and III 
cutaneous melanoma that got the approval form US#FDA. Relapse#free survival was 
significantly prolonged (p= 0.006, HR= 1.30) compared to observational group. 
Unfortunately, the data did not show a survival benefit. The toxicities considerably affect 
quality of life over the course of the treatment. The most common toxicity is neutropenia. 
Interleukin#2 (IL#2) was approved by US#FDA for the treatment of adults with advanced 
metastatic melanoma. IL#2 toxicity can involve multiple organ system, most significantly 
cardiovascular, respiratory, and excretory system. Most of the toxicity is related to the 
capillary leak syndrome. To improve the activity of immunotherapy, combining different 
chemotherapy agents (Biochemotherapy, BCT) and vaccines has been reported. All of 
studies concluded that BCT is associated with increased toxicity and the highest response 
rate is about 50%. A metaanalysis of BCT by the Cochrane Collaboration included 2,625 
patients. The response rate is increased in the group of BCT, but no difference in overall 
survival. (p= 0.31, HR 0.89) 
,/	
Melanoma has a unique relationship to the immune system with the development of 
spontaneous tumor#specific immune responses in patients. For this reason, melanoma has 
been a frequently targeted disease in the development of cancer vaccines. The various 
vaccines were used in the treatment of melanoma including DNA vaccine, dendritic cell 
vaccines, peptide#based vaccines, and viral vaccines. Although vaccines have been 
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demonstrated to produce immunologic responses, unfortunately, no clinical benefit has 
been demonstrated in the previous large randomized vaccine trials performed in melanoma 
in the adjuvant setting.              
,%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!		
Despite of increasing understanding the biology of melanoma, the novel therapeutic agents 
that developed based on the new knowledge with some demonstrated promising antitumor 
effect in several clinical trials. Ipilimumab (MDX#010) is an IgG1 antibody. The several of 
phrase II trials of ipilimumab demonstrated a promising 1#year OS of over 47% and a 2#year 
OS of over 30% (compare to 25% of 1#year survival from meta#analysis). A double–blinded 
phrase III randomized study is ongoing. The in depth other agents such as Bevacizumab, 
Thalidomide is beyond the scope of this review.   
The discovery of +,, (+,, # -( and .& alterations in melanoma has supported the 
development of various rational therapeutic approaches. Sorafenib, PLX4032, and 
GSK2118436 are the effective +, inhibitors. Most of the studies still ongoing, hopefully 
these new agents may be a novel effective treatment options for the patients with advanced 
melanoma in the near future.   
,'$	!	
Although, melanoma is a relatively radio#resistance tumor, undoubtedly, radiation is an 
effective palliative treatment for the 40 #50% of patients who develop unresectable, locally 
recurrent, and/or metastatic disease resulting in bone pain, spinal core compression, tumor 
hemorrhage, and central nervous system dysfunction secondary to cerebral metastases.   
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
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Malignant melanoma of GI tract is uncommon especially primary GI melanoma. History 
taking and careful physical examination is the first step of approach to rule out the primary 
other sources. Skin, eye and rectal examination should be mandatory performed. 
Investigation including endoscopy, ultrasonography, contrast GI studies, CT scan, MRI, and 
PET scan can be used for different purposed. Prognosis is quite poor, particularly in 
secondary GI melanoma. Anorectal melanoma and small bowel is the most common site in 
the primary and metastatic GI melanoma respectively. Surgery is still the mainstay of the 
treatment for localized primary disease. Extensive surgical resection is reserved for selected 
patients. Melanoma is one of the most common tumors that metastasis to GI tract. The 
median survival is usually less than year and estimated 5#year survival is less than 10%. 
Palliative surgical resections are recommended for symptoms relieved. Moreover, it can be 
prolonged survival in the subgroup that completely tumor removal was achieved. 
Unfortunately, most of the cases after resection will experience recurrence of the diseases. 
Then, the current adjuvant treatment such as immunotherapy, chemotherapy, targeted 
therapy, and vaccination may play the important role in this setting.        
1$
Agrawal S, Yao TJ, Coit DG. (1999) Surgery for melanoma metastatic to the gastrointestinal 
tract. ,/, Vol. 6, No. 4, (June 1999), pp. 336#344.  
www.intechopen.com

	
				
	
		

" 
Agrawal D, Tannous GC, Chak A. (2010) Primary malignant melanoma of the hepatic duct: 
a case report. 	
 -, Vol. 72, No. 4, (October 2010), pp. 845#846. 
Akaraviputh T, Arunakul S, Lohsiriwat V, Iramaneerat C, Trakarnsanga A. (2010) Surgery 
for gastrointestinal malignant melanoma: experience from surgical training center. 
"0	

, Vol. 16, No. 6, (February 2010), pp. 745#748. 
Albert JG, Gimm O, Stock K, Bilkenroth U, Marsch WC, Helmbold P. (2007) Small bowel 
endoscopy is crucial for diagnosis of melanoma metastases to the small bowel: a 
case of metachronous small bowel metastases and review of the literature. 

+

, Vol. 17, (2007), pp. 335#338. 
Avital S, Romaguera RL, Sands L, Marchetti F, Hellinger MD. (2004) Primary malignant 
melanoma of right colon.  
,

, Vol. 70, No. 7, (July 2004), pp. 649#
651. 
Balch CM, Gershenwald JE, Soong SJ, et al. (2009) Final Version of 2009 AJC Melanoma 
Staging and Classification. 0)/, Vol. 27, No. 36, (December 
2009), pp. 6199#6206.    
Bastiaannet E, Hoekstra HJ, Hoekstra OS. (2011) Melanoma, Positron Emission 
Tomography. 

, Vol. 727, (May 2011), pp. 123#139. 
Bender GN, Maglinte DD, McLarney JH, Rex D, Kelvin FM. (2001) Malignant melanoma: 
patterns of metastasis to the small bowel, reliability of imaging studies, and clinical 
relevance.  
,
0	

, Vol. 96, No. 8, (August 2001), pp. 
2392#2400. 
Blecker D, Abraham S, Furth EE, Kochman ML. (1999) Melanoma in the gastrointestinal 
tract.  
,
0	

, Vol. 94, No. 12, (December 1999), pp. 
3427#3433. 
Brady MS, Kavolius JP, Quan SH. (1995) Anorectal melanoma. A 64#year experience at 
Memorial Sloan#Kettering Cancer Center. 


)+
, Vol. 38, 
No. 2, (February 1995), pp. 146#151. 
Cadili A. (2009) Primary melanoma of the esophagus: A rare and challenging problem. 


0, Vol. 102, No. 9, (September 2009), pp. 883#884. 
Cagir B, Whiteford MH, Topham A, Rakinic J, Fry RD. (1999) Changing epidemiology of 
anorectal melanoma. 

  
 )  +
, Vol. 42, No. 9, (September 
1999), pp. 1203#1208. 
Caudie AS, Ross MI. (2011) Metastectomy for stage IV melanoma: for whom and how 
much? /)(,
, Vol. 20, No. 1, (January 2011), pp. 
133#144. 
Chalkiadakis G, Wihlm JM, Morand G, Weill#Bousson M, Witz JP. (1985) Primary malignant 
melanoma of the esophagus.  
,    
, Vol. 39, No. 5, (May 
1985), pp. 472#475. 
Chang F, Deere H. (2006) Esophageal melanocytosis morphologic features and review of the 
literature. ,
#12*

, Vol. 130, No. 4, (April 2006), 
pp. 552#557. 
Cheung MC, Perez EA, Molina MA, Jin X, Gutierrez JC, Franceschi D, Livingstone AS, 
Koniaris LG. (2008) Defining the role of surgery for primary gastrointestinal tract 
melanoma. 0	

, Vol. 12, No. 4, (April 2008), pp. 731#
738. 
Chong AE, Karnell LH, Menck HR. (1998) The National Cancer Data Base report on 
cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past 
decade. The American College of Surgeons Commission on Cancer and the 
American Cancer Society. )
, Vol. 83, No. 8, (October 1998), pp. 1664#1678. 
www.intechopen.com

	
	

	

	


"!
Crippa F, Leutner M, Belli F, Gallino F, Greco M, Pilotti S, Cascinelli N, Bombardieri E. 
(2000) Which kinds of lymph node metastases can FDG PET detect? A clinical study 
in melanoma. 0(


, Vol. 41, No. 9, (September 2000), pp. 1491#
1494.  
Crippa S, Bovo G, Romano F, Mussi C, Uggeri F. (2004) Melanoma metastatic to the 
gallbladder and small bowel: report of a case and review of the literature. 

+

, Vol. 14, No. 5, (October 2004), pp. 427#430.  
Dasgupta T, Brasfield R. (1964) Metastatic Melanoma. A clinicopathological study. )
, 
Vol. 17, (October 1964), pp. 1323#1339. 
Davies MA, Gershenwald JE. Targeted therapy for melanoma: a primer. /
)(,
, Vol. 20, No. 1, (January 2010), pp. 165#180.  
De la Pava S, Nigogosyan G, Pickren JW, et al. (1963) Melanosis of the esophagus. )
, 
Vol. 16, (1963), pp. 48#50. 
Essner R. (2003) Surgical Treatment of malignant melanoma.  
  )  (
,
, Vol. 83, No. 1, (February 2003), pp. 109#156.   
Essner R, Lee J, Wanek LA, Itakura H, Morton DL. (2004) Contemporary surgical treatment 
of advanced#stage melanoma. ,

, Vol. 139, No. 9, (September 2004), 
pp.961#966. 
Galloro G, Inzirillo A, Magno L, Diamantis G, Inzirillo M, Pastore A, Ruggiero S, Mosella G. 
(2011) Multiple nodular lesions by colonic metastatic malignant melanoma. 


2


, Vol. 41, No. 2, (February 2009), pp. 169. 
Gabali AM, Priebe P, Ganesan S. (2008) Primary melanoma of small intestine masquerading 
as gastrointestinal stromal tumor: a case report and literature review.  
,


, Vol.74, No. 4, (April 2008), pp. 318#321. 
Garrett K, Kalady MF. (2010) Anal neoplasms. /)(,
, Vol. 
90, No. 1, (February 2010), pp. 147#161. 
Gong L, Li YH, Zhao JY, Wang XX, Zhu SJ, Zhang W. (2008) Primary malignant melanoma 
of the liver: A case report. "0	

, Vol. 14, No. 31, (August 
2008), pp. 4968#4971. 
Gutman H, Hess KR, Kokotsakis JA, Ross MI, Guinee VF, Balch CM. (2001) Surgery of 
abdominal metastases of cutaneous melanoma. " 0  
, Vol. 25, 
No. 6, (June 2001), pp. 750#758. 
Homsi J, Grimm JC, Hwu P. (2010) Immunotherapy of melanoma: an update. 
/)(,
, Vol. 20, No. 1, (January 2010), pp. 145#163.  
Hulshof MC, Van Haaren PM, Zum Vörde Sive Vörding PJ, Krishnadath S, Marsman WA, 
Van Berge Henegouwen MI, Geijsen ED, Crezee J. (2010) Radiotherapy combined 
with hyperthermia for primary malignant melanomas of the esophagus. 



-, Vol. 23, No. 8, (November 2010), pp. E42#47. 
Ishizone S, Koide N, Karasawa F, Akita N, Muranaka F, Uhara H, Miyagawa S. (2008) 
Surgical treatment for anorectal malignant melanoma: report of five cases and 
review of 79 Japanese cases. &
0)


, Vol. 23, no. 12, 
(December 2008), pp.1257#62. 
Joob AW, Haines GK, Kies MS, Shields TW. (1995) Primary malignant melanoma of the 
esophagus!  
 ,    
, Vol. 60, No. 1, (July 1995),  
pp. 217#222. 
Katz SC, Bowne WB, Wolchok JD, Busam KJ, Jaques DP, Coit DG. (2007) Surgical 
management of melanoma of the gallbladder: a report of 13 cases and review of the 
literature. ,
 0  
, Vol. 193, No. 4, (April 2007), pp. 493# 
497.  
www.intechopen.com

	
				
	
		

"
Kenny B, Dotto J, Homer R, Shafi N, Davydova L. Primary malignant melanoma of the 
transverse colon: Report of a case and review of the literaure. &
0
#, Vol. 15, No. 4, (October 2007), 401#407. 
Khalid U, Saleem T, Imam AM, Khan MR. (2011) Pathogenesis, diagnosis and management 
of primary melanoma of the colon. "0/, Vol. 9, No. 14, 
(February 2011), pp. 1#9. 
Kim HS, Kim EK, Jun HJ, Oh SY, Park KW, Lim do H, Lee SI, Kim JH, Kim KM, Lee DH, Lee 
J. (2010) Noncutaneous malignant melanoma: a prognostic model from a 
retrospective multicenter study. ))
, Vol. 28,No. 10, (April 2010), pp. 1#8.  
Kimura H, Kato H, Sohda M, Nakajima M, Fukai Y, Miyazaki T, Masuda N, Manda R, 
Fukuchi M, Ojima H, Tsukada K, Kuwano H. (2005) Flat#type primary malignant 
melanoma of the esophagus treated by EMR: case report. 	
-, 
Vol. 61, No. 6, (May 2005), pp. 787#789. 
Klas JV, Rothenberger DA, Wong WD, Madoff RD. (1999) Malignant tumors of the anal 
canal: the spectrum of disease, treatment, and outcomes. )
, Vol. 85, No. 8, 
(April 1999), pp. 1686#1693. 
Kranzfelder M, Seidl S, Dobritz M, Brücher BL. (2008) Amelanotic esophageal malignant 
melanoma: case report and short review of the literature. )
 +
 
	

, Vol. 2, No. 2, (July 2008), pp. 224#231. 
Kumar R, Alavi A. (2005)  Clinical applications of fluorodeoxyglucose##positron emission 
tomography in the management of malignant melanoma. )
 / 
/, Vol. 17, No. 2, (March 2005), pp. 154#159.   
Lagoudianakis EE, Genetzakis M, Tsekouras DK, Papadima A, Kafiri G, Toutouzas K, 
Katergiannakis V, Manouras A. (2006) Primary gastric melanoma: a case report. 
"0	

, Vol. 12, No. 27, (July 2006), pp. 4425#4427. 
Lens M, Bataille V, Krivokapic Z. (2009) Melanoma of the small intestine.  
 2

/, Vol. 10, No. 5, (May 2009), pp. 516#521. 
Li B, Lei W, Shao K, Zhang C, Chen Z, Shi S, He J. (2007) Characteristics and prognosis of 
primary malignant melanoma of the esophagus. 
+

, Vol. 17, No. 4, 
(August 2007), pp. 239#242. 
Liang KV, Sanderson SO, Nowakowski GS, Arora AS. (2006) Metastatic malignant 
melanoma of the gastrointestinal tract. )#

, Vol. 81, No. 4, (April 
2006), pp. 511#516.  
Manola J, Atkins M, Ibrahim J, Kirkwood J. (2000) Prognostic factors in metastatic 
melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. 0
)/, Vol. 18, No. 22, (November 2000), pp. 3782#3793.  
Manouras A, Genetzakis M, Lagoudianakis E, Markogiannakis H, Papadima A, Kafiri G, 
Filis K, Kekis PB, Katergiannakis V. (2007) Malignant gastrointestinal melanomas of 
unknown origin: should it be considered primary? "0	

, 
Vol. 13, No. 29, (August 2007), pp. 4027#4029. 
Martinez SR, Young SE. (2008) A rational surgical approach to the treatment of distant 
melanoma metastases. )
 

+

3, Vol. 34, No. 7, (November 2008), 
pp. 614#620. 
Moore WD. (1857) Recurrent melanosis of the rectum after previous removal from the verge 
of the anus in a man aged 65. 2
, Vol. 1, (1857), pp. 290#294. 
Nilsson PJ, Ragnarsson#Olding BK. (2010) Importance of clear resection margins in anorectal 
malignant melanoma.  
 0
, Vol. 97, No. 1, (January 2010), 
pp. 98#103. 
www.intechopen.com

	
	

	

	


""
Ollila DW, Hsueh EC, Stern SL, Morton DL. (1999) Metastasectomy for recurrent stage IV 
melanoma. 0   /, Vol. 71, No. 4, (August 1999)  
pp. 209#213. 
Panagiotou I, Brountzos EN, Bafaloukos D, Stoupis C, Brestas P, Kelekis DA. (2002) 
Malignant melanoma metastatic to the gastrointestinal tract. 
 +

, 
Vol. 12, No. 2, (April 2002), pp. 169#173. 
Pantalone D, Taruffi F, Paolucci R, Liguori P, Rastrelli M, Andreoli F. (2000) Malignant 
melanoma of the rectum.  
 -
 0  
, Vol. 166, No. 7, (July 
2000), pp. 583#584. 
Patnana M, Bronstein Y, Szklaruk J, Bedi DG, Hwu WJ, Gershenwald JE, Prieto VG, Ng CS. 
(2011) Multimethod imaging, staging, and spectrum of manifestations of metastatic 
melanoma. )+, Vol. 66, No. 3, (March 2011), pp. 224#236.  
Pessaux P, Pocard M, Elias D, Duvillard P, Avril MF, Zimmerman P, Lasser P. (2004) 
Surgical management of primary anorectal melanoma.  
 0
, 
Vol 91, No. 9, (September 2004), pp.1183#1187. 
Poggi S, McNiff JFM, Hwu WJP, Bayar S, Salem RR. (2000) Colonic melanoma, primary or 
regressed primary. 0)	

, Vol. 30, No. 4, (June 2000), pp. 
441#444.   
Pommer B, Probst A, Messmann H. (2008) Gastric metastases from malignant melanoma. 
-, Vol. 40, Suppl. 2, (September 2008), E30#1.  
Prakoso E, Fulham M, Thompson JF, Selby WS. (2011) Capsule endoscopy versus positron 
emission tomography for  detection of small: a pilot study. 	

- (Febuary 1) (Epub ahead of print) 
Prichard RS, Hill AD, Skehan SJ, O’Higgins NJ. (2002) Positron emission tomography for 
staging and management of malignant melanoma.  
  0  
, 
Vol. 89, No. 4, (April 2002), pp. 389#396. 
Row D, Weiser MR. (2009) Anorectal Melanoma. Clinics in Colon and Rectal Surgery, Vol. 
22, No. 2, (May 2009), pp 120#126. 
Sabanathan S, Eng J, Pradhan GN. (1989) Primary malignant melanoma of the esophagus. 
,
    	

, Vol. 84, No. 2, (December 1989), pp.  
1475#1481. 
Sachs DL, Lowe L, Chang AE, Carson E, Johnson TM. (1999) Do primary small intestinal 
melanomas exist? Report of a case. 0
,
,

, 
Vol. 41, No. 6, (December 1999), pp. 1042#1044.  
Safioleas M, Agapitos E, Kontzoglou K, Stamatakos M, Safioleas P, Mouzopoulos G, 
Kostakis A. (2006) Primary melanoma of the gallbladder: Does it exist? "
0	

, Vol. 12, No. 26, (July 2006), pp. 4259#4261. 
Sanchez AA, Wu TT, Prieto VG, Rashid A, Hamilton SR, Wang H. (2008) Comparison of 
primary and metastatic malignant melanoma of the esophagus: clinicopathologic 
review of 10 cases. ,
  # 1 2*

, Vol. 132, No. 10, 
(October 2008), pp. 1623#1629. 
Sanki A, Scolyer RA, Thompson JF. (2009) Surgery for melanoma metastases of the 
gastrointestinal tract: indications and results. -
0/, 
Vol. 35, No. 3, (March 2009), pp. 313#319. 
Schuchter LM, Green R, Fraker D. (2000) Primary and metastatic diseases in malignant 
melanoma of the gastrointestinal tract. )
//, Vol. 12, No. 2, 
(March 2000), pp. 181#185. 
Shia J. (2010) An update on tumors of the anal canal. ,
  # 1 2*


, Vol. 134, No. 11, (November 2010), pp. 1601#1611. 
www.intechopen.com

	
				
	
		

$##
Slingluff CL Jr, Vollmer RT, Seigler HF. (1990) Anorectal melanoma: clinical characteristics 
and results of surgical management in twenty#four patients. 
, Vol. 107, No. 
1, (January 1990), pp.1#9. 
Sondak VK, Gonzalez RJ, Kudchadkar R. Adjuvant therapy for melanoma: a surgical 
perspective.  / )  ( ,
, Vol. 20, No. 1, (January 
2011), pp. 105#114. 
Spanknebel K, Kaufman HL. (2004) Surgical treatment of stage IV melanoma. ) 

, Vol. 22, No. 3, (May 2004), pp. 240#250. 
Stringa O, Valdez R, Beguerie JR, Abbruzzese M, Lioni M, Nadales A, Iudica F, Venditti J, 
San Roman A. (2006) Primary  amelanotic melanoma of the esophagus. &

0
, Vol. 45, No. 10, (October 2006), pp. 1207#1210.  
Suzuki H, Nakanishi Y, Taniguchi H, Shimoda T, Yamaguchi H, Igaki H, Tachimori Y, Kato 
H. (2008) Two cases of early#stage esophageal malignant melanoma with long#term 
survival. #&
, Vol. 58, No. 7, (July 2008), pp. 432#435. 
Tanaka K, Toyoda H, Hamada Y, Aoki M, Kosaka R, Noda T, Katsurahara M, Nakamura M, 
Ninomiya K, Inoue H, Imoto I. (2008) Duodenal metastasis of malignant melanoma 
observed by magnification endoscopy. -, Vol. 40, Suppl. 2, (September 
2008), E6#7. 
Tessier DJ, McConnell EJ, Young#Fadok T, Wolff BG. (2003) Melanoma metastatic to the 
colon: case series and review of the  
literature with outcome analysis. 


)+
, Vol. 46, No. 4, (April 2003), 
pp. 441#447. 
Thibault C, Sagar P, Nivatvongs S, Ilstrup DM, Wolff BG. (1997) Anorectal melanoma##an 
incurable disease? 


)+
, Vol. 40, No. 6, (June 1997), pp. 
661#618. 
Wagner MS, Shoup M, Pickleman J, Yong S. (2000) Primary malignant melanoma of the 
common bile duct: a case report and review of the literature. ,
#1
2*

, Vol. 124, No. 3, (March 2000), pp. 419#422. 
Weinstock MA. (1993) Epidemiology and prognosis of anorectal melanoma. 	

, 
Vol. 104, No. 1, (January 1993), pp. 174#178. 
Wong SL, Coit DG. (2004) Role of surgery in patients with stage IV melanoma. )

//, Vol. 16, No. 2, (March 2000), pp. 150#160. 
Wood TF, DiFronzo LA, Rose DM, Haigh PI, Stern SL, Wanek L, Essner R, Morton DL. 
(2001) Does complete resection of melanoma metastatic to solid intra#abdominal 
organs improve survival? ,   /, Vol. 8, No. 8, (September 
2001), pp. 658#662.  
Yeh JJ, Shia J, Hwu WJ, Busam KJ, Paty PB, Guillem JG, Coit DG, Wong WD, Weiser MR. 
(2006) The role of Abdomino –perineal resection as surgical therapy for anorectal 
melanoma. ,
, Vol. 244, No. 6, (December 2006), pp. 1012#1017. 
Young SE, Martinez SR, Essner R. (2006) The role of surgery in treatment of stage IV 
melanoma. 0 /, Vol. 94, No. 4, (September 2006), pp. 344#
351. 
Zaide EC. (1963) Melanoma maligno do coledoco. Arq Oncol, Vol. 5, (1963), pp. 254#255. 
www.intechopen.com
Melanoma in the Clinic - Diagnosis, Management and
Complications of Malignancy
Edited by Prof. Mandi Murph
ISBN 978-953-307-571-6
Hard cover, 310 pages
Publisher InTech
Published online 23, August, 2011
Published in print edition August, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
This book provides an excellent overview of how melanoma is treated in the clinic. Since oncologists and
clinicians across the globe contributed to this book, each area also explores the unique burdens that
geographical areas experience from melanoma subtypes and how these are treated in different settings. It
also includes several chapters that illustrate novel methods for diagnosing melanoma in the clinic using new
technologies, which are likely to significantly improve outcomes. Several chapters cover surgical techniques
and other present very rare or challenging clinical cases of melanoma and how these were treated. The book
is geared towards informing clinicians and even patients how melanoma arises, what tools are available and
which decisions need to be made by patients and their families in order to treat this devastating disease.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Thawatchai Akaraviputh and Atthaphorn Trakarnsanga (2011). Surgical Management of Malignant Melanoma
of Gastrointestinal Tract, Melanoma in the Clinic - Diagnosis, Management and Complications of Malignancy,
Prof. Mandi Murph (Ed.), ISBN: 978-953-307-571-6, InTech, Available from:
http://www.intechopen.com/books/melanoma-in-the-clinic-diagnosis-management-and-complications-of-
malignancy/surgical-management-of-malignant-melanoma-of-gastrointestinal-tract
© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed
under the terms of the Creative Commons Attribution-NonCommercial-
ShareAlike-3.0 License, which permits use, distribution and reproduction for
non-commercial purposes, provided the original is properly cited and
derivative works building on this content are distributed under the same
license.
